Over 1,000 protesters demonstrate against Carney’s investment summit in Toronto
More than 1,000 demonstrators gathered in downtown Toronto on Monday to protest against an investment summit organized by…
Broker/Dealers Race to Build the Bridge to Wealth
When asked what the three biggest initiatives Osaic wanted him to focus on when he took the job…
Lessons in starting up: How an entrepreneurial couple built a joint legacy
When Vineet Agrawal and Sikha Agrawalla became entrepreneurs, for many, it could appear to be yet another audacious…
Fujitsu Releases Open Quantum Application Research Package as Open Source
Fujitsu Releases Open Quantum Application Research Package as Open Source
Skip to content Insider Brief Fujitsu released…
UK pay growth slows to 3.9% before crunch interest rates decision | Economics
Wage growth in the UK has slowed as workers come under pressure from a renewed cost of living…
State pension likely to rise by 3.9% next April – BBC
State pension likely to rise by 3.9% next April BBCState pension likely to rise by £488 a year in…
NSF Funds Pilot Program to Support Small Businesses in Accelerating Commercialization of Their Late-Stage Deep-Technology and Avoid the “Valley of Death”
The U.S. National Science Foundation’s Directorate for Technology, Innovation and Partnerships (TIP) announced a $20 million investment to…
Objectors protest against Microsoft's major Leeds data centre – BBC
Objectors protest against Microsoft’s major Leeds data centre BBCHundreds protest against Microsoft AI datacentres planned to be built in…
Do we even own anything anymore?
Sonya Joseph grew up on a tree-lined street in Brooklyn. “Around the block we had nice small mom…
State pension likely to rise by £488 a year in April
The state pension is likely to rise by £488 next April to £13,036.40 a year, new official figures…
Watch: First-Time Entrepreneurs Aged 18 To 30 To Benefit From New Financial Support Scheme
The support will cover fees linked to the company’s incorporation as well as annual return fees for five…
Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab…